Indian stocks: Visit www.stage2stocks.com →

Revolution Medicines, Inc.

Stage 2 · Advancing · week 26

As of Oct 22, 2026, Revolution Medicines is in Stage 2, the uptrend phase, now in week 26 (since Apr 20, 2026). It closed at $187.69, 15.1% below its 52-week high and above its 200-day average, which is rising.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More about the company

$187.69
-2.75% today
$40.2B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is RVMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 47w
S4 16w
S2 26w
S2 27w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 9w → S3 4w → S4 7w → S1 4w → S2 47w → S3 6w → S4 16w → S1 7w → S4 8w → S1 2w → S2 26w → S3 2w → S2 27w current
Total tracked: 165 weeks across 13 stage runs.

RVMD among Biotechnology13th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…13RVMDStage 2 · wk 2698−1.6%
vs 52W High
-15.1%
$52.98 lo$221.15 hi
15.1% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 26
1w13w26w
Week 26, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
22.0%
200 DMA: $153.83 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.73x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-1.6%
3M
-0.8%
6M
+39.6%
YTD
+137.5%
1Y
+250.9%
Scan Membership
Breakout Watch
Latest: 2024-02-06
5 appearances in last 60 days. First seen: 2020-11-25.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 26 · Vol 0.73x
2026-10-21S2
Wk 26 · Vol 0.89x
2026-10-20S2
Wk 26 · Vol 1.36x
2026-10-19S2
Wk 26 · Vol 0.99x
2026-10-16S2
Wk 26 · Vol 1.50x
2026-10-15S2
Wk 25 · Vol 0.79x
2026-10-14S2
Wk 25 · Vol 1.25x
2026-10-13S2
Wk 25 · Vol 1.51x
2026-10-12S2
Wk 25 · Vol 0.86x
2026-10-09S2
Wk 25 · Vol 1.14x
2026-10-08S2
Wk 24 · Vol 2.57x
2026-10-07S2
Wk 24 · Vol 0.62x
Moving averages & range
50 DMA
$201.85
200 DMA
$153.83
52W High
$221.15
52W Low
$52.98
5D Low
$177.96
Resistance levels (recent highs)
20d High
$207.68
60d High
$221.15
120d High
$221.15
250d High
$221.15
Next resistance
+10.7%
to 20d High
ROE
-79.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 15.4

Revolution Medicines: quick answers

What stage is Revolution Medicines in?

As of Oct 22, 2026, Revolution Medicines (RVMD) is in Stage 2, the uptrend phase. It entered Stage 2 on Apr 20, 2026 and is in week 26. What the four stages mean

Is Revolution Medicines in an uptrend?

Yes. Revolution Medicines is in a Stage 2 uptrend. It trades 22.0% above its 200-day average, which is rising.

How far is Revolution Medicines from its 52-week high?

Revolution Medicines closed at $187.69 on Oct 22, 2026, 15.1% below its 52-week high of $221.15. Its 52-week low is $52.98.

How has Revolution Medicines performed over the past year?

As of Oct 22, 2026, Revolution Medicines is up 250.9% over the past year and up 137.5% so far in 2026.

Which sector and industry is Revolution Medicines in?

Revolution Medicines is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.